Home > Publications database > Mapping dopamine with positron emission tomography: A note of caution > print

001     868033
005     20210130004030.0
024 7 _ |a 10.1016/j.neuroimage.2019.116203
|2 doi
024 7 _ |a pmid:31539589
|2 pmid
024 7 _ |a 1053-8119
|2 ISSN
024 7 _ |a 1095-9572
|2 ISSN
024 7 _ |a 2128/24118
|2 Handle
024 7 _ |a altmetric:72453725
|2 altmetric
024 7 _ |a WOS:000509662600032
|2 WOS
037 _ _ |a FZJ-2019-06626
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Dagher, Alain
|0 P:(DE-HGF)0
|b 0
|e Corresponding author
245 _ _ |a Mapping dopamine with positron emission tomography: A note of caution
260 _ _ |a Orlando, Fla.
|c 2020
|b Academic Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1580455553_18560
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Positron emission tomography (PET) imaging is uniquely suited to measuring neurotransmitter signaling in the human brain. PET tracers for neurotransmitter studies are ligands of the receptor or enzyme of interest labelled with positron emitting isotopes, usually 11C of 18F. By far the most frequent target of PET neurotransmitter imaging is dopamine, and the most commonly used tracer is [11C]raclopride, an antagonist of the dopamine D2 receptor (D2R), first developed by researchers at the Karolinska Institute (Farde et al., 1986).
536 _ _ |a 571 - Connectivity and Activity (POF3-571)
|0 G:(DE-HGF)POF3-571
|c POF3-571
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Palomero-Gallagher, Nicola
|0 P:(DE-Juel1)131701
|b 1
|u fzj
773 _ _ |a 10.1016/j.neuroimage.2019.116203
|g p. 116203 -
|0 PERI:(DE-600)1471418-8
|p 116203 -
|t NeuroImage
|v 207
|y 2020
|x 1053-8119
856 4 _ |y OpenAccess
|u https://juser.fz-juelich.de/record/868033/files/1-s2.0-S1053811919307943-main.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://juser.fz-juelich.de/record/868033/files/1-s2.0-S1053811919307943-main.pdf?subformat=pdfa
909 C O |o oai:juser.fz-juelich.de:868033
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 1
|6 P:(DE-Juel1)131701
913 1 _ |a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|1 G:(DE-HGF)POF3-570
|0 G:(DE-HGF)POF3-571
|2 G:(DE-HGF)POF3-500
|v Connectivity and Activity
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEUROIMAGE : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NEUROIMAGE : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
920 1 _ |0 I:(DE-Juel1)INM-1-20090406
|k INM-1
|l Strukturelle und funktionelle Organisation des Gehirns
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-1-20090406
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21